Plants That Produce Psychedelics: What the Research Shows

Bottom line: Scientists have engineered a tobacco plant to produce five psychedelic tryptamines, which may suggest a more sustainable way to make these substances for future research and potential medical applications, but the science is still in early stages and the compounds are not yet approved for use.

Scientists have engineered a tobacco plant to produce five well-known psychedelic tryptamines — psilocybin, psilocin, DMT, bufotenin, and 5-MeO-DMT — in one plant for the first time. This could change how these substances are made, used, and studied, but the science is still in its early stages.

A team of researchers has created a system that allows a single tobacco plant to produce these five compounds, which are found in nature but often come from endangered species or require complex extraction methods. The breakthrough is a first step toward more sustainable ways of making these substances, which could support future research and potential medical applications. However, the production levels are currently low, and the compounds themselves are not yet approved for use in therapies.

The researchers used a clever strategy: they reconstructed the full biosynthetic pathways for all five tryptamines in the plant. This involved combining enzymes from multiple species and modifying them through protein design to work together in one system. While the method is promising, it’s not yet efficient enough for large-scale production. The engineered plants don’t produce the same levels of these compounds as their natural sources, which means the technology is still being refined.

This development could have major environmental benefits. Some of these compounds are currently harvested from wild plants or animals, such as the Sonoran Desert toad, which produces bufotenin and 5-MeO-DMT. Overharvesting and habitat loss have made this species endangered. By producing these substances in plants, scientists may be able to reduce the pressure on wild populations and help protect ecosystems. It could also provide a more stable supply for research and, one day, for potential medical use.

Psychedelic tryptamines have shown early promise in mental health research. Psilocybin, for example, has been tested in clinical trials for depression, and DMT has been explored for addiction and anxiety. But these are still early-stage findings. The compounds are not yet approved for medical use, and more studies are needed to understand their safety, effectiveness, and long-term impact.

This research does not prove that these substances are safe or effective for treatment. The compounds are not yet approved by regulatory agencies, and the engineered plants do not currently produce the same levels of these compounds as natural sources. Yields are lower, which may limit large-scale use until production can be improved.

Can I grow my own psychedelic tryptamines using this method? No. This research is still in its early stages. The production of these substances is heavily regulated, and it is not currently possible for individuals to grow their own for therapeutic use.

Are psychedelic tryptamines safe for human consumption? Not yet. Research is ongoing, and more studies are needed to understand the risks and benefits.

Can I use psychedelic tryptamines to treat my mental health condition? No. These substances are not currently approved for therapeutic use. Individuals should not attempt to use them for mental health treatment without consulting a qualified healthcare professional.

How do the yields obtained from the engineered plants compare to those obtained from natural sources? The yields are currently lower. This could limit their potential for large-scale production.

What are the potential environmental benefits of producing psychedelic tryptamines in plants? It could reduce pressure on wild populations and help conserve species that are over-harvested for their psychoactive compounds.

Sources

• ¶Complete biosynthesis of psychedelic tryptamines from three kingdoms in plants
• ¶Three Naturally-Occurring Psychedelics and Their Significance in the Treatment of Mental Health Disorders
• ¶Psychedelics and Autism Therapy: A Review of Current Research and Future Directions

Educational Disclaimer

This article is for informational and educational purposes only. It is not medical advice, mental health advice, diagnosis, treatment guidance, or a recommendation to use any substance, supplement, therapy, or protocol.

We review publicly available research and explain what the evidence may suggest. Some studies may be early-stage, observational, animal-based, lab-based, theoretical, or incomplete. Always consult a qualified professional before making health-related decisions.

Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.